I saw an email from Gerald a couple weeks ago stating that once the LP002 data is released, they will be able to do something more "concrete" with their Lympro partner, which he thought might add shareholder value. In the email he threw out again the possibility of a diagnostic spin off, but to be honest, that part of the email seemed vague. I couldn't tell if he was speaking of something that was imminent... or a year off. But I'm pretty certain the "concrete" thing regarding the partnership will be fairly soon following the release of the LP002 data.